Invasive behavior of ulcerative colitis-associated carcinoma is related to reduced expression of CD44 extracellular domain: comparison with sporadic colon carcinoma by Mikami, Tetuo et al.
RESEARCH Open Access
Invasive behavior of ulcerative colitis-associated
carcinoma is related to reduced expression of
CD44 extracellular domain: comparison with
sporadic colon carcinoma
Tetuo Mikami
*, Tsutomu Yoshida, Yoshiko Numata, Masaomi Kikuchi, Kayo Araki, Norihiro Nakada and
Isao Okayasu
Abstract
Background: To elucidate relations of invasion of ulcerative colitis (UC)-associated carcinoma with its prognosis,
the characteristics of invasive fronts were analyzed in comparison with sporadic colonic carcinomas.
Methods: Prognoses of 15 cases of UC-associated colonic carcinoma were compared with those of sporadic colon
carcinoma cases, after which 75 cases of sporadic invasive adenocarcinoma were collected. Tumor budding was
examined histologically at invasive fronts using immunohistochemistry (IHC) of pancytokeratin. Expressions of beta-
catenin with mutation analysis, CD44 extracellular domain, Zo-1, occludin, matrix matalloproteinase-7, laminin-5g2,
and sialyl Lewis X (Le
X) were immunohistochemically evaluated.
Results: UC-associated carcinoma showed worse prognosis than sporadic colon carcinoma in all the cases, and
exhibited a tendency to become more poorly differentiated when carcinoma invaded the submucosa or deeper
layers than sporadic carcinoma. When the lesions were compared with sporadic carcinomas considering
differentiation grade, reduced expression of CD44 extracellular domain in UC-associated carcinoma was apparent.
Laminin-5g2 and sialyl-Le
X expression showed a lower tendency in UC-associated carcinomas than in their sporadic
counterparts. There were no differences in the numbers of tumor budding foci between the two lesion types, with
no apparent relation to nuclear beta-catenin levels in IHC.
Conclusions: UC-associated carcinoma showed poorer differentiation when the carcinoma invaded submucosa or
deeper parts, which may influence the poorer prognosis. The invasive behavior of UC-associated carcinoma is more
associated with CD44 cleavage than with basement membrane disruption or sialyl-Lewis-antigen alteration.
Background
It is certain that patients with ulcerative colitis (UC) are
more liable to develop a colon carcinoma than those
without UC [1]. In our experience, UC-associated carci-
noma tends to be more poorly differentiated when the
carcinoma invades deeper than the submucosa, even if it
is well differentiated in the lamina propria. Although the
prognosis of UC-associated carcinoma had been
regarded as grave in the past [2,3], clinicopathological
studies suggested similarity to sporadic colorectal
carcinoma [2-4]. However, it is still controversial, and
the difference of invasion between UC-associated carci-
noma and sporadic colon carcinoma has not yet been
elucidated.
Focusing on factors for invasion, we earlier compared
expression of cell adhesion molecules in UC-associated
carcinomas with those in sporadic colonic adenocarcino-
mas, revealed significantly decreased expressions of
CD44 and alpha-catenin and altered expression of beta-
catenin in UC-associated lesions [5]. However, it was
unclear whether or not UC-associated carcinoma has a
more invasive behavior and whether or not carcinoma
cell differentiation influences the biological behavior in
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we tried to compare UC-associated carcinoma cases
with sporadic colorectal adenocarcinoma counterparts,
focusing on prognosis, tumor cell differentiation, tumor
budding, and several protein expressions.
Recently, tumor budding has become considered a
major malignant characteristic of colorectal carcinomas
[6,7]. Defined as the presence of isolated single cells or
small cell clusters (≤4 cells) scattered in the stroma at
invasive fronts [6], this features loss of both glandular
differentiation and cell cohesion that is crucial for the
development of high-invasive properties. Tumor bud-
ding has been reported to be a risk factor for lymphatic
involvement and lymph node metastasis in sporadic col-
orectal carcinomas [8,9]. However, the prognoses of
patients with UC-associated carcinomas are not known.
Regarding cell adhesion molecules, the down-regulation
of CD44 expression is reported to correlate with
metastasis and poor prognosis in various types of car-
cinoma [10,11]. Recently, it was reported that CD44
reduction is caused in part by the proteolysis-based
cleavage of its extracellular domain, which occurs in
many malignant tumors [12]. Zo-1 and occludin are
tight junction-associated proteins, which seal the cells
together and prevent diffusion of solutes from the out-
side [13]. It was reported that both occludin and Zo-1
showed reduced expression in poorly differentiated
gastrointestinal carcinoma [13].
When beta-catenin translocates into the nucleus and
binds to the T-cell factor, it acts as a transcription factor
for various genes [14], including matrix metalloprotei-
nase-7 (MMP-7, matrilysin) [15], which is known to
play roles in extracellular matrix degradation [16,17].
One of the main targets of MMP-7 in epithelial base-
ment membranes is the laminin-5 isoform, formed by
association of a3, b3, and g2 chains. Specific cleavage of
the laminin-5g2 chain by members of the MMP family
has been proposed to favor cell migration [17,18].
A modified blood group ABO/Lewis antigen, sialyl
Lewis X (Le
X) is present on the surfaces of human leu-
kocytes [19,20]. It was also reported to be expressed in
colonic carcinoma cells while sialyl 6-sulfo Le
X is char-
acteristic of normal colonic epithelium [21], and it was
considered to play an important role in metastasis
through the binding to E-selectin on endothelial cells
[22]. Increased expression of sialyl Le
X correlates with a
poor prognosis in patients with colorectal carcinoma,
demonstrating relations to the depth of tumor invasion,
lymph node metastasis, lymphatic invasion, and the dis-
ease stage [23,24].
In the present study, expression of CD44 extracellular
domain, Zo-1, occludin, MMP-7, and laminin-5g2i n
association with beta-catenin nuclear localization, and
levels of sialyl Le
X were immunohistochemically
investigated along with tumor budding in UC-associated
and sporadic colon carcinomas, with the aim of eluci-
dating differences in mechanisms of invasion and biolo-
gical behavior between the two types of colon
carcinomas in relation to prognoses.
Methods
From the pathology files of Kitasato University East
Hospital and three other affiliated hospitals, 15 cases of
UC-associated colonic carcinoma were collected, and 12
of those 15 were located in the left hemicolon. Histolo-
gically, 6 cases were well differentiated adenocarcinoma,
4 cases being moderately differentiated adenocarcinoma,
and 5 cases being poorly differentiated adenocarcinoma
(including signet ring cell carcinoma). Duration of ill-
ness from onset to surgical resection was from 6 to 19
years (mean, 13.1 years). The lesions were histologically
confirmed by three expert pathologists (TM, TY, and
IO) according to the criteria of Riddell et al. [25].
Prognosis analysis
A total of 300 consecutive cases of sporadic advanced
adenocarcinoma were collected from the pathology files
of the Kitasato University East Hospital from 1999 to
2000. The prognosis data of 15 UC-associated adenocar-
cinomas, and these 300 sporadic adenocarcinoma cases,
were examined from their clinical charts. When calcu-
lating overall survival in the present study, only deaths
from carcinoma were considered in the analysis.
Histopathological examination
As sporadic counterparts, sporadic invasive adenocarci-
noma cases of 5 times the number of UC-associated
lesion cases were collected for the two histologic groups:
30 cases of well differentiated and 45 cases of moder-
ately to poorly differentiated adenocarcinoma (moder-
ately differentiated, 37 cases; poorly differentiated, 8
cases). The lesions were histologically confirmed by
three pathologists (TM, TY, and IO), according to the
World Health Organization histological typing [26]. In
order to guarantee the material quality for immunohis-
tochemical reaction and DNA analysis, the additional 75
cases from 2003 to 2004 were collected, not including
the above 300 cases.
All histopathological materials were fixed in 10% buf-
fered formalin and routinely processed for embedding in
paraffin. From the invasive carcinoma lesions, both UC-
associated and sporadic, paraffin blocks, including the
deepest invasion parts, were chosen for examination.
The differentiation of adenocarcinoma at both the sur-
face and deep parts were histologically examined for
each lesion.
Immunohistochemical staining of 4-micrometer-thick
paraffin sections was performed using a commercial kit
Mikami et al. Diagnostic Pathology 2011, 6:30
http://www.diagnosticpathology.org/content/6/1/30
Page 2 of 9(EnVision+, Dako, Glostrup, Denmark). The primary
antibodies used and methods for antigen retrieval are
listed in Table 1. Microwave oven heating (500 W,
5 min, ×3 times) was done with a target retrieval solution
(pH 9.0, Dako) for cytokeratin, and with a target retrieval
solution (pH 6.0, Dako) for MMP-7, beta-catenin,
laminin-5g2, and sialyl Le
X to retrieve antigenic activity.
Protease treatment (15 min, 37°C) was done for Zo-1
and occludin. The sections were subsequently incubated
with the primary antibodies at 4°C overnight. After
processing according to the manufacturer’sp r o t o c o l s ,
3,3’-diaminobenzidine was used as the final chromogen,
and nuclei were counter-stained with hematoxylin or
methyl green.
Evaluation of tumor budding
Isolated single carcinoma cells and small cell clusters
composed of fewer than five carcinoma cells were
defined as tumor budding foci in the stroma at actively
invasive tumor margins [6]. The numbers of tumor bud-
ding foci on pancytokeratin-stained slides were counted
using a ×10 objective lens along the invasive front of
carcinomas for at least 1.5 cm in length per case, after
which the value per 1 cm was calculated.
Expression of CD44 extracellular domain, MMP-7, laminin-
5g2, sialyl Le
X, Zo-1, occludin, and beta-catenin
At the invasive fronts of carcinoma lesions, immunor-
eactivity for CD44 extracellular domain, MMP-7,
laminin-5g2, and sialyl Le
X was evaluated and semi-
quantified according to the classification of Sinicrope
et al. [27] focusing on both staining intensity and fre-
quency of stained cells. The intensity was scored: weak,
1; moderate, 2; intense, 3. For frequency, positive cells
were expressed as the percentage of the total number of
cells in the invasive front and assigned to 1 of 5 cate-
gories: 0, <5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; 4, >76%.
Immunoreactivity scores for each lesion were calculated
by multiplication of the values for the two parameters.
For Zo-1 and occludin staining, the expression was
observed at the cell surface of the lumen composed of
adenocarcinoma cells. The expression pattern, linear or
dot-like, was investigated. For beta-catenin, when more
than 20% of the carcinoma cells showed nuclear immu-
noreactivity [28], the case was judged as nuclear beta-
catenin positive (Table 1). Sinicrope’s method, described
above, was used for the beta-catenin membranous and
cytoplasmic expressions [27].
DNA extraction and sequencing analysis
DNA was extracted from formalin-fixed, paraffin-
embedded tissue samples. Five 10-μm-thick sections
were cut and deparaffinized in xylene before dehydra-
tion with 100% ethanol. After nuclear staining with
hematoxylin, lesions were microdissected under a
microscope with disposable scalpels, and DNA was
extracted with an extraction kit (QIAamp DNA Mini
Kit, Qiagen, Hilden, Germany). The collected samples
were treated with proteinase K, and lysates were pro-
cessed according to the manufacturer’s protocols.
Examination of the exon 3 sequence of the beta-
catenin gene was done according to the methods used
Table 1 Antibodies used for the immunohistochemical examination
Antibody Clone Source Dilution Antigen retrieval Interpretation
CD44 extracellular
domain
(aminoterminal end)
Polyclonal,
Ab64929
Abcam, Cambridge,
MA
1/50 Not applied Sinicrope’s method*
Zo-1 Polyclonal,
61-7300
Zymed, South San
Francisco, CA
1/100 Protease treatment (15 min, 37°C) Linear or dot-like
Occludin Polyclonal,
71-1500
Zymed 1/100 Protease treatment (15 min, 37°C) Linear or dot-like
MMP-7 Monoclonal,
141-7B2
Daiichi Fine
Chemical, Takaoka,
Japan
1/200 Microwave treatment for 15 min
(Dako target retrieval solution
[pH 6.0])
Sinicrope’s method*
Pancytokeratin Monoclonal,
MNF116
Dakocytomation,
Glostrup, Denmark
1/50 Microwave treatment for 15 min
(Dako target retrieval solution
[pH 9.0])
For evaluation of tumor budding
beta-Catenin Monoclonal,
14/beta-
catenin
BD Transduction
laboratories,
Lexington, KY
1/200 Microwave treatment for 15 min
(Dako target retrieval solution
[pH 6.0])
Nuclear, more than 20% judged as positive;
membranous and cytoplasmic, Sinicrope’s
method*
Laminin-5g2 Monoclonal,
4G1
Dakocytomation 1/50 Microwave treatment for 15 min
(Dako target retrieval solution
[pH 6.0])
Sinicrope’s method*
Sialyl Lewis X Monoclonal,
FH6
Ohtsuka
Pharmaceutical,
Tokushima, Japan
1/2000 Microwave treatment for 15 min
(Dako target retrieval solution
[pH 6.0])
Sinicrope’s method*
￿ Sinicrope’s method is described in Reference [27].
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by polymerase chain reaction (PCR) using TaKaRa
ExTaq polymerase (Takara Bio Inc., Ohtsu, Japan) in a
volume of 20 μlw i t hf o r w a r d( 5 ’-ATTTGATG-
GAGTTGGACATGG-3’) and reverse (5’-TCTTCCTCA
GGATTGCCTT-3’) primers with the conditions:
33 cycles of 94°C for 0.5 min, 55°C for 1 min, and 72°C
for 1 min. Subsequently, 5 μl aliquots of reaction pro-
ducts were applied to agarose gel electrophoresis to
confirm the PCR reaction. As a negative control, water
was supplied instead of template DNA for each
examination.
The remaining 15 ml aliquots of PCR products were
purified using a QIAquick PCR Purification Kit (Qiagen)
and sequenced using a BigDye Terminator Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA)
according to the manufacturers’ protocols. The DNA
sequence data were collected and analyzed on an ABI
Prism 3100 automated DNA sequencer (Applied Biosys-
tems). If a mutation was found using the forward PCR
primer, the reverse PCR primer was used to confirm the
mutation.
Statistical analysis
Statistical analysis was performed using the c
2 and
Mann-Whitney U tests. When more than 3 groups were
compared, the Kruskal Wallis test with the Mann-Whit-
ney U test was applied. Prognosis was analyzed by the
Kaplan-Meier method with the log-rank test. All calcu-
lations were performed using SPSS computer software
(SPSS Inc., Chicago, IL, USA), and P-values less than
0.05 were considered statistically significant.
Results
Prognosis was analyzed for Stage 2 and 3 cases (9 UC-
associated and 244 sporadic carcinomas). As for overall
survival of all cases, UC-associated carcinoma showed
worse prognosis than sporadic carcinoma (P =0 . 0 1 0 )
(Figure 1). However, when the cases were limited to well
differentiated carcinomas, no significant difference was
shown (P = 0.136). Similarly, the cases limited to moder-
ately to poorly differentiated ones, no significant differ-
ence was shown (P = 0.071). Clinicopathological data for
the 15 UC-associated and 75 sporadic colon carcinoma
cases are summarized in Table 2. There were no differ-
ences in the rates of lymph node metastasis between the
2 groups (Table 2). In comparison between the surface
and deep parts of the lesions, UC-associated carcinomas
tended to become more poorly differentiated when the
carcinoma invaded the submucosa or deeper (Table 3).
The rate of the cases which showed poorer differentiation
at the deep part was significantly higher in UC-associated
carcinoma (10 of 15 cases, 66.7%) than in sporadic colon
carcinoma (25 of 75 cases, 33.3%) (P = 0.033).
The lesions were divided according to their differen-
tiation, and UC-associated and sporadic carcinomas
were compared in each differentiation category. CD44
extracellular domain showed lower expression in UC-
associated carcinoma than in sporadic carcinoma, in
both the well-differentiated category and the poorly dif-
ferentiated category (P = 0.010, P < 0.001, respectively)
(Figure 2) in invasive fronts. As the colon carcinoma
cases would generally be divided into two categories:
well to moderately differentiated and poorly differen-
tiated cases [26], comparison between the 2 categories
revealed that CD44 extracellular domain expression was
significantly higher in sporadic well to moderately differ-
entiated carcinoma than in the UC-associated counter-
parts (P = 0.002). There were no differences in tumor
budding and MMP-7 expression. Laminin-5g2a n ds i a l y l
Le
X both showed higher expression in sporadic carcino-
mas than in their UC-associated counterparts, without
statistical significance (Table 4) (Figure 3). In division
into the 2 categories, sialyl-Le
X expression was signifi-
cantly higher in sporadic well to moderately differen-
tiated carcinoma than in their UC-associated
counterparts (P = 0.016).
Expression of both Zo-1 and occludin was observed as
lines or dots on the apical cell surface of a lumen or cell
adhesion site. At the invasive fronts of UC-associated
carcinoma of the 6 cases of well differentiated carci-
noma, Zo-1 and occludin were expressed as a line pat-
tern in 5 (83.3%) and a dot pattern in 1 (16.7%),
respectively; and of the 9 cases of moderately to poorly
Figure 1 Prognoses were analyzed for cases of ulcerative
colitis (UC)associated and sporadic colon carcinomas of stages
2 and 3. For all cases, UC-associated carcinoma showed worse
overall survival than sporadic carcinoma (P = 0.010). When cases
were limited to well differentiated carcinomas, no significant
difference was shown (P = 0.136). Similarly, the cases limited to
moderately to poorly differentiated ones, no significant difference
was shown (P = 0.071).
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in 5 (55.6%) and a dot pattern in 4 (44.4%). On the
other hand, all 30 (100%) well differentiated sporadic
lesions showed linear expression of Zo-1 and occludin.
For the 45 moderately to poorly differentiated cases, 36
(80.0%) showed a linear expression and 9 (20.0%)
showed a dot pattern expression (Figure 2). There were
no significant differences between UC-associated and
sporadic carcinomas.
There were no differences in numbers of tumor bud-
ding foci among the sporadic carcinomas of the right
and left hemicolon and the UC-associated carcinomas
(Table 5). In addition, there were no differences in
tumor budding between nuclear beta-catenin negative
and positive cases of sporadic carcinoma. Cytoplasmic
beta-catenin expression was significantly stronger in
nuclear positive than in nuclear negative cases of spora-
dic carcinoma (Table 6) (Figure 4). In the UC-associated
carcinomas, 1 of 2 nuclear beta-catenin positive lesions
was a signet-ring cell carcinoma mixed with mucinous
carcinomas. Therefore, comparison between nuclear
beta-catenin negative and positive lesions in UC-asso-
ciated carcinoma was not considered appropriate.
Mutations in beta-catenin exon 3 were found in 1 of
32 (3.1%) sporadic carcinomas of the right and 1 of 41
(2.4%) of the left hemicolon, but none were found in the
7 cases of UC-associated carcinomas examined. PCR or
sequencing reactions failed in 11 cases, probably due to
the poor quality of the extracted DNA.
Discussion
In the present study, for overall cases, the prognosis of
UC-associated carcinoma was worse than that of spora-
dic colon carcinoma. However, significant difference was
not shown when the cases were limited to the same
tumor differentiation. Because the UC-associated carci-
noma cases contained much poorly differentiated cases,
and since the number of cases was small, it was difficult
to conclude that the prognosis of UC-associated carci-
noma is definitely worse than that of its sporadic coun-
terpart. However, the character that UC-associated
carcinoma showed poorer differentiation at the invasion
area in the submucosa or deeper parts may influence
the prognosis.
The frequency of beta-catenin gene mutation was low
in both UC-associated and sporadic carcinomas. In the
literature, the frequency in sporadic colorectal carci-
noma has varied from the 0% reported by Garinis et al.
[30] to the percentages of 22% and 26%, respectively,
described by Mirabelli-Primdahl et al.[ 3 1 ]a n dA u s t
et al.[ 3 2 ] .I nc o n t r a s t ,A u s tet al. [32] found no beta-
catenin mutations in UC-associated carcinomas. Garinis
Table 2 Clinicopathological summary of the cases
UC-
associated
Sporadic P
value
Site
Left side 12 41 0.068
Right side 3 34
Histological type
Well differentiated 6 30
Moderately differentiated 4 37
Poorly differentiated (including
signet-ring cell carcinoma)
58
Depth of invasion
Up to MP 2 12 0.79
SS/A or deeper 13 63
Lymph node metastasis
Negative 5 31 0.56
Positive 10 44
Stage
I 2 9 0.14
II 3 22
III 9 44
IV 1 0
UC-ulcerative colitis; MP-muscularis propria; SS-subserosa; A-adventitia.
Table 3 Comparison of histologic type between mucosa and deeper parts (submucosa or deeper) of cancer lesion
UC-associated
(n = 15)
Sporadic
(n = 75)
P value
Mucosa area Deeper area
Well Well 2 25
Well Moderately 5 18
Well Poorly 2 0
Moderately Moderately 1 20
Moderately Poorly 3 7
Poorly Poorly 2 5 0.0062*
Poorer differentiation in deep parts** 10 (66.7%) 25 (33.3%) 0.033*
UC - ulcerative colitis; n - number of cases.
* c
2 test.
** Cases which were shown to be well differentiated at the mucosa and moderately to poorly differentiated at the deep areas, and showed moderately
differentiated at mucosa and poorly differentiated at the deep areas.
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Page 5 of 9Figure 2 Representative photographs of CD44 extracellular domain, Zo-1, and occludin expression.C D 4 4e x t r a c e l l u l a rd o m a i ni sn o t
expressed at the cell membrane of the invasive part of ulcerative colitis (UC)-associated well differentiated carcinoma (A) and a poorly
differentiated carcinoma (B). On the other hand, in a case of sporadic well differentiated (C) and a case of sporadic poorly differentiated
adenocarcinoma (D), membranous expression of CD44 extracellular domain is observed. Linear expression of Zo-1 (E) and occludin (F) is seen at
the luminal surface in a case of UC-associated well differentiated carcinoma. However, in a UC-associated poorly differentiated case, dot-like
expression of both Zo-1 (G) and occludin (H) is observed on the cell surface.
Table 4 Tumor differentiation and budding, and expression of CD44 extracellular domain, MMP-7, laminin-5g2, and
sialyl Le
X in invasive fronts
n Tumor budding (/cm) CD44 MMP-7 Laminin-5g2 Sialyl Le
X
Sporadic cancer
Well differentiated 30 206.7 ± 293.9 5.5 ± 2.8* 4.2 ± 3.4 5.2 ± 2.7 3.2 ± 3.3
Moderetely differentiated 37 264.0 ± 240.6 5.1 ± 2.6 4.4 ± 3.4 5.7 ± 2.7 4.2 ± 3.1
Poorly differentiated 8 395.8 ± 280.5 6.6 ± 2.6** 2.6 ± 2.9 4.6 ± 3.5 1.1 ± 0.8
UC-cancer
Well differentiated 6 146.2 ± 239.4 2.2 ± 1.5* 3.8 ± 2.8 4.0 ± 2.6 1.3 ± 2.3
Moderately differentiated 4 157.0 ± 178.7 2.8 ± 1.5 4.7 ± 1.5 5.0 ± 1.2 1.0 ± 0.0
Poorly differentiated 5 145.8 ± 213.4 1.2 ± 1.6** 1.0 ± 1.0 1.8 ± 2.0 1.4 ± 1.5
MMP - matrix metalloproteinase; n - number of cases; Le
X - Lewis X; UC - ulcerative colitis.
*P= 0.010.
** P < 0.001.
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strand conformation polymorphism method while Mira-
belli-Primdahl et al. [31] and Aust et al. [32] used PCR-
direct sequencing. Although the frequency of beta-cate-
nin mutations thus appears to vary, in the present study,
nuclear expression did not show any positive relation
with tumor budding, a morphological feature of invad-
ing carcinomas. We conclude that the role of beta-
catenin in invasion may be limited.
In our previous study, it was shown that expression of
the CD44 standard form, variant 3, and variant 6 was
reduced in UC-associated neoplasia compared to their
sporadic counterparts [5]. In the present study, CD44
extracellular domain expression was significantly lower
in UC-associated carcinoma than in its sporadic coun-
terparts. Not the splicing variant but CD44 extracellular
domain cleavage is considered to play a critical role in
CD44-madiated tumor cell migration by regulating the
interaction between CD44 and extracellular matrix
[33,34]. It may play a key role in invasion of UC-
associated carcinoma and its loss may be related with
poor prognosis. On the other hand, tight junction asso-
ciated proteins showed no difference. Although lesions
with poorer differentiation showed reduced expression
(dot pattern) of Zo-1 and occludin, the barrier function
of tight junction may be essential for epithelial cells
including carcinoma to maintain the microenvironment.
The expression of both laminin-5g2, a marker of base-
ment membrane disruption, and sialyl Le
X, a cell surface
antigen suggestive of a poor prognosis, showed here
paradoxically lower tendency in UC-associated carcino-
mas than in sporadic counterparts. In invasion of UC-
associated carcinoma, adhesion between CD44 molecule
and extracellular matrix might be more important than
basement membrane disruption or the alteration of sia-
lyl Lewis antigens.
The average figures of tumor budding tended to be
lower in UC-associated carcinomas than those in spora-
dic carcinomas, even in moderately to poorly differen-
tiated groups. This may not be concordant with the
findings that UC-associated carcinoma showed poorer
differentiation in the submucosa or deeper parts. How-
ever, histologically, different from sporadic carcinomas,
poorly differentiated UC-associated carcinoma cells
often tended to show trabecular arrangement or much
Figure 3 Representative expression of matrix metalloproteinase-7 (MMP-7), laminin-5g2, and sialyl Lewis X (Le
X) in an ulcerative colitis
(UC)-associated colon carcinoma case (A-C) and a sporadic colon carcinoma case (D-F). While MMP-7 expression is low in the UC-
associated carcinoma with limited tumor budding (A), strong expression is seen in a sporadic carcinoma with frequent tumor budding (D).
Laminin-5g2 expression observed in invasive fronts of both UC-associated (B) and sporadic (E) cases, especially at tumor budding foci. Note that
while no expression of Le
X is apparent in a UC-associated case (C), strong immunoreactivity is evident in the sporadic lesion (F).
Table 5 Tumor budding in UC-associated and sporadic
colon carcinomas
n Foci of tumor budding (/cm)
Sporadic cancer, right 34 278.4 ± 316.1
Sporadic cancer, left 41 235.9 ± 225.9
UC cancer 15 148.9 ± 200.9
UC - ulcerative colitis; n-number of cases.
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ding. Therefore, this discordance may be related with
characteristics of invasion of UC-associated carcinoma.
Because UC-associated carcinoma showed poorer dif-
ferentiation when it invaded the submucosa or deeper
layers, early detection of UC-associated neoplastic
lesions before submucosal invasion is considered impor-
tant. Recent advances in dye spraying and magnifying
endoscopy for the colon have made it possible to detect
early neoplastic lesions in UC follow-up patients [35,36].
Such endoscopic detection should allow great improve-
ment in outcome for affected patients.
Conclusions
UC-associated carcinoma showed poorer differentiation
when the carcinoma invaded submucosa or deeper,
which might influence its poorer prognosis. Its invasive
behavior is more associated with CD44 cleavage than
with basement membrane disruption or sialyl Lewis
antigen alteration.
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